Zofenopril in the treatment of patients with arterial hypertension and stable coronary heart disease: effects on oxidative stress and flowdependent vasodilatation
https://doi.org/10.15829/1728-8800-2011-3-15-21
Abstract
Aim. To compare the effects of ACE inhibitors zofenopril and perindopril on endothelial function and oxidative stress (OS) in patients with stable CHD and AH.
Material and methods. In total, 40 patients with stable CHD (Functional Class II-III effort angina) and Stage 1-2 AH received zofenopril (7,5-30 mg/d; mean dose 18,6±8,8 mg/d; n=17) or perindopril (2-8 mg/d; mean dose 4,1±2,1 mg/d; n=23) for 12 weeks. At baseline and in the end of the study, all patients underwent reactive hyperemia test (RHT), to assess flow-dependent vasodilatation of brachial artery, and the measurement of OS parameters (malone dialdehyde, MDA, in low-density lipoproteins, MDALDL) and antioxidant parameters (superoxide dismutase (SOD) and glutathione peroxidase (GPO) activity in erythrocytes).
Results. In both groups, a similar reduction in systolic and diastolic blood pressure levels was observed. In the zofenopril group, a significant elevation in brachial artery diameter increase during RHT, a significant increase in GPO activity, and some reduction in MDALDL levels were observed, which points to antioxidant system (AOS) activation and OS reduction. No similar changes of these parameters were observed in the perindopril group.
Conclusion. In patients with stable CHD and AH, zofenopril, but not perindopril, reduced OS severity and increased AOS system activity, which was associated with improved endothelial-dependent vasodilatation.
About the Authors
F. T. Ageev
A.L. Myasnikov Research Institute of Clinical Cardiology, Russian Cardiology Scientific and Clinical complex
Russian Federation
Moscow
Russian Federation
Moscow
A. G. Ovchinnikov
A.L. Myasnikov Research Institute of Clinical Cardiology, Russian Cardiology Scientific and Clinical complex
Russian Federation
Moscow
Russian Federation
Moscow
A. G. Plisyuk
A.L. Myasnikov Research Institute of Clinical Cardiology, Russian Cardiology Scientific and Clinical complex
Russian Federation
Moscow
Russian Federation
Moscow
N. E. Arzamastseva
A.L. Myasnikov Research Institute of Clinical Cardiology, Russian Cardiology Scientific and Clinical complex
Russian Federation
Moscow
Russian Federation
Moscow
B. D. Kulev
A.L. Myasnikov Research Institute of Clinical Cardiology, Russian Cardiology Scientific and Clinical complex
Russian Federation
Moscow
Russian Federation
Moscow
A. E. Kuz’mina
A.L. Myasnikov Research Institute of Clinical Cardiology, Russian Cardiology Scientific and Clinical complex
Russian Federation
Moscow
Russian Federation
Moscow
I. F. Patrusheva
A.L. Myasnikov Research Institute of Clinical Cardiology, Russian Cardiology Scientific and Clinical complex
Russian Federation
Moscow
Russian Federation
Moscow
References
1. Steinberg D, Parthasarathy S, Carew T, et al. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 1989; 320: 915-24.
2. Steinberg D, Witztum J. Lipoproteins and atherogenesis: current concepts. JAMA 1990; 264: 3047-52.
3. Witztum J, Steinberg D. Role of oxidized low density lipoprotein in atherosclerosis. J Clin Invest 1991; 88: 1785-92.
4. Witztum J. The oxidation hypothesis atherosclerosis. Lancet 1994; 344: 793-5.
5. Napoli C, Ignaro L. Nitric oxide and atherosclerosis. Nitric Oxide 2001; 5: 88-97.
6. Ferrari R, Agnoletti L, Comini L, et al. Oxidative stress during myocardial ischemia and heart failure. Eur Heart J 1998; 19: B2-11.
7. Witz G. Biological interactions of alpha, beta-unsaturated aldehydes. Free Radiol Biol Med 1989; 7: 333-49.
8. Esterbauer H, Gebicki J, Puhl H, Jurgens G. The role of lipid peroxidation and antioxidants in oxidative modification of LDL. Free Radic Biol Med 1992; 13: 341-90.
9. Hess M, Manson N, Okabe E. Involvement of free radical in the pathophysiology of ischemic heart disease. Can J Physiol Pharmacol 1982; 60: 1382-9.
10. Hess M, Manson N. Molecular oxygen: friend and foe. The role of the oxygen free radical system in the calcium paradox, the oxygen paradox and ischemia/reperfusion injury. J Moll Cell Cardiol 1984; 16: 969-85.
11. Ланкин В., Коган А., Ковалевская А. и др. Ферменты детоксикации активных форм кислорода и липоперекисей при экспериментальной ишемии и инфаркте миокарда. Бюлл эксперим биол мед 1982; 93: 58-60.
12. Зенков Н., Кандалинцева Н., Ланкин В. и др. Фенольные биоантиоксиданты. Изд-во СО РАМН, Новосибирск 2003; 328 стр.
13. Scribner A, Loscalzo J, Napoli C. The effect of angiotensin-converting enzyme inhibition on endothelial function and oxidant stress. Eur J Pharmacol 2003; 482: 95-9.
14. Celemajer D, Sorensen K, Gooch V, et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992; 340: 1111-5.
15. Недосугова Л., Ланкин В., Балаболкин М. и др. Взаимосвязь между компенсацией углеводного обмена и выраженностью проявлений окислительного стресса при сахарном диабете II типа. Бюлл эксперим биол мед 2003; 136: 152-5.
16. SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fraction. N Engl J Med 1992; 327: 685-91.
17. SAVE Study. Effect of captopril on mortality in patients with left ventricular dysfunction after myocardial infarction. Results of the Survival and Ventricular Enlargement trial. N Engl J Med 1992; 327: 669-77.
18. HOPE Investigators. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342: 145-53.
19. Fox K. European Trial On Reduction of Cardiac Events with Perindopril in Stable Coronary Artery Disease Investigators: efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: Randomized, double-blind, placebo-controlled, multicentre trial (the EUROPA Study). Lancet 2003; 362: 782-8.
20. Rolland P, Souchet T, Friggi A, et al. Aorta viscoelasticity and arterial histopathology of atherosclerotic pigs treated by angiotensin converting enzyme inhibition. J Hypertens 1991; 9: S178-9.
21. Buikema H, Monnink S, Tio R, et al. Comparison of zofenopril and lisinopril to study the role of the sulfhydryl-group in improvement of endothelial dysfunction with ACE-inhibitors in experimental heart failure. Br J Pharmacol 2000; 130: 1999-2007.
22. Gonzalez W, Fontaine V, Pueyo M, et al. Molecular plasticity of vascular wall during N (G)-nitro-L-arginine methyl esterinduced hypertension modulation of proinflammatory signals. Hypertension 2000; 36: 103-9.
23. Haek T, Keidar S, Mei Y, Aviram M. Effects of angiotensinconverting enzyme inhibitors on LDL lipid peroxidation and atherosclerosis in apolipoprotein E deficient mice. Circulation 1995; 92: 2290-8.
24. Haek T, Attias J, Smith J, et al. Antiatherosclerotic and antioxidative effects of captopril in apolipoprotein E deficient mice. J Cardiovasc Pharmacol 1998; 31: 540-4.
25. Haek T, Attias J, Coleman R, et al. The angiotensin-converting enzyme inhibitor, fosinopril and angiotensin II receptor antagonist, losartan, inhibit LDL oxidation and attenuate atherosclerosis independent of lowering blood pressure, in apolipoprotein E deficient mice. Cardiovasc Res 1999; 44: 579-87.
26. Napoli C, Cicala C, D’Armiento F, et al. Benefical effects of the ACE-inhibition with zofenopril on plaque formation and low-density lipoprotein oxidation in Watanabe heritable hyperlipidemic rabbits. Gen Pharmacol 1999; 33: 467-77.
27. Keidar S, Attias J, Coleman R, et al. Attenuation of atherosclerosis in apolipoproteinE-deficient mice by ramipril is dissociated from its antihypertensive effect and from potentiation of bradykinin. J Cardiovasc Pharmacol 2000; 35: 64-72.
28. de Nigris F, D’Armiento F, Somma P, et al. Chronic treatment with sulfhydryl angiotensin-converting enzyme inhibitors reduce susceptibility of LDL to in vitro oxidation, formation of oxidation-specific epitopes in the arterial wall, and atherogenesis in apolipoprotein E knockout mice. Int J Cardiol 2001; 81: 107-15.
29. Kowala M, Grove R, Aberg G. Inhibitors of angiotensin converting enzyme decrease early atherosclerosis in hyperlipidemic hamsters. Fosinopril reduces plasma cholesterol and captopril inhibits macrophage-foam cell accumulation independently of blood pressure and plasma lipids. Atherosclerosis 1994; 108: 61-72.
30. Daemen M, Lombardi D, Bosman F, Schwartz S. Angiotensin II induces smooth muscle cell proliferation in the normal and injured rat arterial wall. Circ Res 1991; 68: 450-6.
31. Li J, Hirose N, Kawamura M, Arai Y. Antiatherogenic effect of angiotensin converting enzyme inhibitor (benazepril) and angiotensin II receptor antagonist (valsartan) in the cholesterol-fed rabbits. Atherosclerosis 1999; 143: 315-26.
32. Linz W, Wiemer G, Gohlke P, et al. Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Pharmacol Rev 1995; 47: 25-49.
33. TREND Study. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing Endothelial Dysfunction) Study. Circulation 1996; 94: 258-65.
34. Anderson TJ, Overhiser RW, Haber H, Charbonneau FA. Сomparitive study of four anti hypertensive agents on endothelial function in patients with coronary disease. JACC 1998; 31 (2, suppl A): 327A. Abstract.
35. Napoli C, Sica V, de Nigris F, et al. Sulfhydril angiotensinconverting inhibition induces sustained reduction of systemic oxidative stress and improves the nitric oxide pathway in patients with essential hypertension. Am Heart J 2004; 148: 1-7.
36. Chopra M, Beswick H, Clapperton M, et al. Antioxidant effects of angiotensin converting enzyme (ACE) inhibitors: free radical and oxidant scavenging are sulfhydryl dependent, but lipid peroxidation is inhibited by both sulfhydryl- and nonsulfhydrylcontaing ACE inhibitors. J Cardiovasc Pharmacol 1992; 19: 330-40.
37. Prasad A, Mincemoyer R, Quyyumi AA, et al. Anti-ischemic effects of angiotensin-converting enzyme inhibition in hypertension. JACC 2001; 38: 1116-22.
38. Pepine CJ, Rouleau JL, Annis K, et al. Effects of angiotensin-converting enzyme inhibition on transient ischemia: The quinapril anti-ischemia and symptoms of angina reduction (QUASAR) trial. JACC 2003; 43: 2049-50.
39. Ambrosione E, Borghi C, Magnani B, et al. Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators. The effect of thе angiotensin-converting enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. N Engl J Med 1995; 332: 80-5.
40. Borghi C, Ambrosione E. Survival of Myocardial Infarction Long-Term Evaluation-2 Working Party: Double -blind comparison between zofenopril and lisinopril in patients with acute myocardial infarction: results of the Survival of Myocardial Infarction Long-term Evaluation-2 (SMILE-2) study. Am Heart J 2003; 145(1): 88-97.
41. Ambrosione E, Bachelli S, Borghi C, et al. Anti-ischemic effects of angiotensin-converting enzyme inhibitors: a future therapeutic perspective J Cardiovasc Pharmacol 2001; 37 (suppl): S3-9.
Review
For citations:
Ageev F.T., Ovchinnikov A.G., Plisyuk A.G., Arzamastseva N.E., Kulev B.D., Kuz’mina A.E., Patrusheva I.F. Zofenopril in the treatment of patients with arterial hypertension and stable coronary heart disease: effects on oxidative stress and flowdependent vasodilatation. Cardiovascular Therapy and Prevention. 2011;10(3):15-21. (In Russ.) https://doi.org/10.15829/1728-8800-2011-3-15-21
Views:
1052
Email this article 
